PRODUCTION OF POLIOVIRUS AT HIGH TITERS FOR VACCINE PRODUCTION
    55.
    发明申请
    PRODUCTION OF POLIOVIRUS AT HIGH TITERS FOR VACCINE PRODUCTION 审中-公开
    生产用于疫苗生产的高分子杆菌

    公开(公告)号:US20130052224A1

    公开(公告)日:2013-02-28

    申请号:US13660412

    申请日:2012-10-25

    发明人: John Alfred Lewis

    摘要: Described is a process for producing poliovirus, the process comprising: a) providing a serum-free suspension culture of cells, which are primary human retina (HER) cells that have been immortalized by expression of adenovirus E1 sequences, b) infecting the cells with poliovirus, at a cell density of between 2×106 cells/ml and 150×106 cells/ml, and c) harvesting poliovirus at a time of between 12 and 48 hours after infection.

    摘要翻译: 描述了产生脊髓灰质炎病毒的方法,该方法包括:a)提供通过腺病毒E1序列表达而永生化的原代人视网膜(HER)细胞的细胞的无血清悬浮培养物,b)用 脊髓灰质炎病毒,细胞密度在2×10 6个细胞/ ml和150×10 6个细胞/ ml之间,和c)在感染后12至48小时之间收获脊髓灰质炎病毒。

    Recombinant human Alpha1-antitrypsin
    56.
    发明授权
    Recombinant human Alpha1-antitrypsin 有权
    重组人α1-抗胰蛋白酶

    公开(公告)号:US08357661B2

    公开(公告)日:2013-01-22

    申请号:US13138912

    申请日:2010-04-20

    IPC分类号: A61K38/14

    CPC分类号: C07K14/8125

    摘要: The present invention relates recombinant human α1-antitrypsin (rhAAT) comprising N-linked glycans, wherein at least 10% of said N-linked glycans are tetra-antennary glycans; and the degree of capping with sialic acid on said N-linked glycans (Z/A) is at least 50%. The invention further relates to rhAAT for use as a medicament, in particular for use in the prevention and/or treatment of a disease associated with AAT deficiency, and/or a disease involving neutrophil-mediated tissue damage.

    摘要翻译: 本发明涉及包含N-连接聚糖的重组人α1-抗胰蛋白酶(rhAAT),其中至少10%的所述N-连接聚糖是四触角聚糖; 并且所述N-连接聚糖(Z / A)上的唾液酸封端度至少为50%。 本发明还涉及用作药物的rhAAT,特别是用于预防和/或治疗与AAT缺乏相关的疾病和/或涉及嗜中性粒细胞介导的组织损伤的疾病。